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Summary: The interferon-inducible enzyme, 2/-5/-oligoadenylate synthetase, was estimated in healthy donors
and in patients before and after subcutaneous application of recombinant interferon beta and gamma. Tests
were carried out with lysates of peripheral blood mononuclear cells, using an established radioenzymatic
assay, and in serum samples, using a new radioimmunoassay. Both test systems substantially yielded the same
results: after a single injection of interferon beta (1 — 5 106IU), 2'-5'-oligoadenylate synthetase increased
in a dose-dependent manner reaching maximal catalytic concentrations in most patients after 24—48 hours
(leukocytes) and 48 — 72 hours (serum). In contrast, interferon gamma (2 —4 106IU) caused only a small
induction of 2/-5/-oligoadenylate synthetase. However, daily application of interferon gamma for 7 days led
to a distinct time-dependent increase of 2/-5/-oligoadenylate synthetase activity concentration during this
observation period. Characteristically, even during daily application, the 2/-5/-oligoadenylate synthetase
activity concentration dropped just 48 — 72 hours after the first injection of interferon beta.
The determination of 2/-5/-oligoadenylate snythetase proved to be useful for optimizing and monitoring
subcutaneous therapy with interferon. The new radioimmunoassay which allows the determination of this
enzyme in serum is superior to other methods used in the past.
Introduction
 u u , * · j u u 1 * 1 * ·have been characterized by abnormal catalytic con-
The treatment of most cells with all kinds of interferon centrations of this enzyme in leukocytes and in serum
leads to the induction of 2/-5/-oligoadenylate (7 — 15). Furthermore, the determination of 2'-5'-oli-
synthetase1) in vitro and in vivo (1 — 3). This enzyme goadenylate synthetase in leukocytes proved to be
is part of the 2/-5/-oligoadenylate system which rep- useful in the follow-up of intravenous (i. v.) and in-
resents one of the effector mechanisms of interferon's tramuscular (i.m.) interferon therapy (16—21). Its
antiviral action and which may also be involved in its measurement was often found to be superior to the
antiproliferative (4, 5) and immunoregulative (6) estimation of interferon in serum, because not only
processes. The determination of 2/-5/-oligoadenylate does it indicate the presence of interferon, but also its
synthetase has been widely used as a quantity in biological activity. 2/-5/-Oligoadenylate synthetase ac-
clinical chemistry: Several interferon-related diseases tivity was also estimated directly in tumour tissue
during therapy with interferon and it was demon-
_ strated that the therapeutic success was correlated
EnZyme: with the induced intratumour enzyme activity con-
2'-5'-oligoadenylate synthetase, EC 2.7.7. - centration (22).
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For clinical studies, most determinations of 2'-5'-
oligoadenylate synthetase have so far been performed
in extracts of leukocytes. Despite their usefulness for
many investigations, these tests are time consuming
and are suitable particularly for retrospective studies
(23). Recently, a sensitive radioimmunoassay has been
developed which permits the determination of 2'-5'-
oligoadenylate synthetase in serum samples (24).
In the present study we compare the 2'-5'-oligoad-
enylate synthetase activity in both leukocytes (using
the radioenzymatic assay according to Schattner (25))
and in serum samples (using the radioimmunoassay
described by Sawai (24)). Blood was obtained from
healthy donors and from patients before and during
therapy with recombinant interferon beta and
gamma, which had been applied subcutaneousely
(s. c.). Our aim was to find out whether or not this
new assay could be used for the determination of 2'-
5'-oligoadenylate synthetase in serum as a follow-up
marker during subcutaneous interferon therapy, since
there were no data in the literature on this question.
Materials and Methods
Individuals
The control group consisted of healthy female and male blood
donors (24—42 years old).
Other blood samples were obtained from patients suffering
from different dermatological diseases.
Blood samples
Heparinized blood was drawn from healthy donors or from
patients, from the latter both before and after s. c. application
of interferon. Leukocytes were isolated by centrifugation using
Lymphoprep (Nyegaard, Oslo, Norway) as described (23). For
in vitro experiments, leukocytes (2 χ 109/1) were incubated at
37 °C for 12, 24, and 48 h with interferon beta or gamma (100
χ 103 IU/1) in minimal essential medium (MEM), supplemented
with human serum (volume fraction 0.05) from AB blood group
donors. After incubation, cell pellets were prepared and frozen
at -70°C until use.
Briefly, 20 μΐ of leukocyte lysate (20 χ 109/1) were bound
to poly(r!)(rC)-agarose beads; after washing, the poly(r!)(rC):
2'-5'-oligoadenylate synthetase complex was mixed with a
5mmol/l [a32P]ATP-containing buffer and incubated for 20
hours at 30 °C for generation of radiolabelled 2'-5'-oligoaden-
ylates.
Subsequently, samples were treated with bacterial alkaline phos-
phatase. The 2/-5/-oligoadenylate cores formed by this process
were separated from 32P by passage through an alumina column.
Eluted 2'-5'-oligoadenylate cores were estimated by Cerenkov-
radiation. Enzyme activity is given as % radioactivity incor-
porated into 2/-5/-oligoadenylate cores per hour per 106 cells.
The 2/-5'-oligoadenylate synthetase activity of patients' samples
was related to an internal standard. For this purpose, lysates
of leukocytes from 5 healthy persons were prepared in large
quantities and frozen in several aliquots at — 70 °C. Samples
of these 5 donors were always analysed in parallel with the
patients' samples. The mean of 2'-5/-oligoadenylate synthetase
activity of the healthy donors was arbitrarily set at 1.0 and the
2/-5/-oligoadenylate synthetase activities of the patients' sam-
ples were related to this value. All experiments were carried
out in duplicate; the CV usually ranged between 4—12%.
Determination of 2'-5 /-oligoadenylate synthetase
activity in serum
The radioimmunoassay of EIKEN (Immunological Laboratory
Kita-ku, Tokyo, Japan), provided by Mecconti, Bad Homburg,
Germany, was used. The test was carried out according to the
manufacturer's instructions:
First, serum samples (50 μΐ) were incubated with poly(rI)(rQ-
agarose beads for 10 minutes at room temperature. After wash-
ing, beads were incubated with 500 μΐ incubation buffer con-
taining unlabelled ATP at a concentration of 40 μιηοΐ/ΐ. After
incubation for one hour at 37 °C (formation of "cold" 2'-5'-
oligoadenylate), 100 μΐ of 125I-labelled 2/-5/-oligoadenylate so-
lution (tracer) and 100 μΐ of antiserum directed against 2'-5'-
oligoadenylate were added, and incubation carried out for an
additional hour at 37 °C (formation of antigen-antibody com-
plex).
Thereafter, samples were centrifuged at 4 °C at 6000 g for 15
minutes, the supernatant was removed and the radioactivity
in the pellet was measured. A calibration curve using known
2'-5'-oligoadenylate concentrations was established; the 2'-5'-
oligoadenylate synthetase activity is expressed as 2'-5'-oligoad-
enylate (pmol/1) produced under the test conditions during one
hour incubation time. The determinations were carried out in
duplicate (CV below 5%).
Interferons and their determination
Recombinant Interferon beta (Betaferon®) and recombinant
Interferon gamma (Polyferon®, 2 χ ΙΟ6 IU corresponding 100
μg) were obtained from Bioferon / Rentschler, Laupheim, Ger-
many. Concentrations of interferon gamma in serum were meas-
ured using the Gamma Interferon IRMA assay from Byk
Sangtec Diagnostica, Dietzenbach, Germany; Interferon beta
in serum was determined using a biological assay as described
(26).
Determination of 2'-5'-oligoadenylate synthetase in
leukocytes
This enzyme was determined by a slightly modified procedure
of the assay according to Schattner (25), and is described in
detail elsewhere (23).
Results
2 /-5 /-Oligoadenylate synthetase activity in
leukocytes of healthy persons
In order to estimate 2/-5/-oligoadenylate synthetase
catalytic concentrations in leukocytes of patients, it
is recommended that they be compared with a refer-
ence collective. For this purpose, lysates of leukocytes
from 5 healthy donors were prepared in large quan-
tities and stored in aliquots at —70 °C. Under these
conditions, the enzyme is stable for several months.
These samples were analysed in parallel with the pa-
tients' samples in all further experiments. Figure 1
shows, as an example, the 2'-5'-oligoadenylate syn-
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Fig. 1. 2/-5'-Oligoadenylate synthetase activity (expressed as
percent radioactivity incorporated per hour per 106 leu-
kocytes) of cell lysates from 5 healthy donors measured
on 5 different days during an observation period of 60
days (reference collective).
thetase activity of these healthy donors measured on
5 different days during a total observation period of
2 months. The mean of 2/-5/-oligoadenylate synthe-
tase activities estimated in percent radioactivity in-
corporated into 2/-5/-oligoadenylate cores per hour
per 106 cells were:
1.91 ± 0.34 (day 1)
2.63 + 0.36 (day 2)
1.24 ± 0.21 (day 3)
2.55 ± 0.59 (day 7)
1.69 ± 0.26 (day 60)
The mean of 2/-5/-oligoadenylate synthetase activity
of these 5 donors estimated in each experiment was
arbitrarily set at 1.0 and patients' samples measured
on the same day were related to this mean. In this
way, determinations of 2/-5/-oligoadenylate synthe-
tase activities in leukocytes can be best followed over
a long time period.
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Fig. 2. Distribution of 2/-5/-oligoadenylate synthetase activity
in lysates of leukocytes from 104 healthy donors in
relation to the reference collective (set at 1.0). Mean:
0.97 ± 0.58.
Figure 2 shows the 2'-5'-oligoadenylate synthetase
activity in leukocytes of healthy persons (related to
reference collectives) measured in our laboratory dur-
ing the last few years. In the majority of cases, the
2/-5/-oligoadenylate synthetase activities of these per-
sons were very similar to those of the respective ref-
erence collective (mean: 0.97 ± 0.58; n = 104). Dis-
tinctly elevated 2'-5'-oligoadenylate synthetase activ-
ities observed in a small number of cases might reflect
the temporary occurrence of hidden viral infections
(see also fig. 3).
2 /-5 /-Oligoadenylate synthetase activity in
leukocytes after in vitro treatment with inter-
ferons
The clinical studies described below were carried out
using recombinant interferon beta and gamma. There-
fore, the effects of these interferons on 2'-5'-oligoad-
enylate synthetase induction were first investigated in
vitro in order to obtain information on their enzyme-
inducing capacity. As shown in table 1, 2'-5'-oligoad-
enylate synthetase was clearly induced by incubation
with interferon beta, whereas only minor effects were
observed when interferon gamma was used.
Tab. 1. Mean 2/-5/-oligoadenylate synthetase activity in leu-
kocytes from 10 healthy donors before and after in
vitro incubation with interferon gamma (100 χ 103
IU/1) and interferon beta (100 χ ΙΟ3 IU/1) for 12, 24
and 48 hours)
Incubation
time
0
12
24
48
Interferon
gamma
0.93
1.03 + 0.66
1.25 + 0.66
0.88 + 0.38
Interferon
beta
+ 0.55*
1.55 + 0.82
2.46 + 0.86
2.37 + 1.07
* 2/-5/-oligoadenylate synthetase activity is expressed in rela-
tion to the reference collective given in figure 1 (arbitrarily
set at 1.0)
2 /-5 /-Oligoadenylate synthetase activity in
serum of healthy persons
Figure 3 shows the basal 2/-5/-oligoadenylate synthe-
tase catalytic concentrations in the sera of 54 healthy
persons. The mean 2/-5/-oligoadenylate concentration
generated during the one hour incubation time was
186 + 84 pmol/1. As already described for lysates of
leukocytes, in a small number of persons the 2'-5'-
oligoadenylate synthetase activity was distinctly ele-
vated. However, no correlation between the 2'-5'-
oligoadenylate synthetase measured in leukocytes (us-
ing the radioenzymatic assay) and in the correspond-
ing sera (using the radioimmunoassay) were detected
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Fig. 3. 2/-5/-Oligoadenylate synthetase activity in serum sam-
ples of 54 healthy donors. Data are expressed as pmol/1
2'-5'-oligoadenylates generated under the test conditions
described. Mean: 186 ±84 pmol/1 · h.
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Fig. 4. Correlation between 2'-5'-oligoadenylate synthetase ac-
tivity in serum (measured by RIA) and in lysates of
leukocytes (measured by radioenzymatic assay). The
enzyme was determined in blood samples of healthy
donors and patients before interferon therapy
(r = 0.011).
(healthy donors and patients before interferon ther-
apy, fig. 4).
•
2'-5'-Oligoadenylate synthetase in serum and
leukocytes during subcutaneous therapy with
interferon beta and gamma (single dose ap-
plication)
Figure 5 shows the changes in 2'-5'-oligoadenylate
synthetase after single s.c. injections of different
amounts of interferon beta. A distinct dose- and time-
dependent elevation of the mean 2'-5'-oligoadenylate
synthetase activity was observed in serum (fig. 5a,
peak at about 48 — 72 hours), as well as in leukocytes
(fig. 5b, peak at about 24 — 48 hours). In addition,
the time course of the interferon concentrations (fig.
5e) as well as those of the 2/-5/-oligoadenylate syn-
thetase induction measured in serum (fig. 5c) and in
lysates of leukocytes (fig. 5d) of three arbitrarily cho-
sen patients in this collective is shown after treatment
with 3 χ 106 IU interferon beta. In all the cases
investigated, enzyme induction occurred, although
there were large individual differences.
Analogous investigations were carried out in patients
after single dose therapy with interferon gamma. As
shown in figure 6a —6d, the induction of 2'-5'-oli-
goadenylate synthetase was much less pronounced
than after treatment with interferon beta.
2 /-5 /-Oligoadenylate synthetase in leuko-
cytes during subcutaneous therapy with in-
terferon beta and gamma (daily dose appli-
cation for 7 days)
Striking differences in 2'-5'-oligoadenylate synthetase
induction were observed after daily application of
interferon beta and gamma: A permanent small in-
crease in the 2/-5/-oligoadenylate synthetase activity
was registered after daily application of interferon
gamma (fig. 7). In contrast, during therapy with in-
terferon beta, the 2/-5/-oligoadenylate synthetase de-
creased at 72 h (3 χ ΙΟ6 IU) or 48 h (5 χ ΙΟ6 IU)
after the first application of the interferon (fig. 8).
Discussion
The estimation of interferon during therapy and for
diagnosis has been performed in many patients in the
past. The purpose was to determine the pharmaco-
kinetics of the different kinds of interferon, to estab-
lish appropriate time schedules for the application,
and to determine the appropriate dose and the manner
of administration (intravenously, intramuscularly or
sucutaneously) for different interferons. These inves-
tigations showed that interferon's half life time in
serum is short and that the detectable concentrations
are rather low. Thus, in our own investigation re-
ported here, we could never detect interferon beta
when the subcutaneously applied dosage was smaller
than 3 χ ΙΟ6 IU per injection. Small, but only tran-
sient concentrations of interferon gamma could be
registered in most patients treated s.c. with 2—4
χ 106 IU. For this reason the determination of the
interferon-induced enzyme, 2/-5/-oligoadenylate syn-
thetase, has some principal advantages compared with
the analysis of interferon. However, there are no data
in the literature concerning the kinetics of 2'-5'-oli-
goadenylate synthetase induction after s.c. applica-
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Fig. 5. 2/-5'-Oligoadenylate synthetase activity in serum and leukocytes after a single s. c. injection of different amounts of
interferon beta during an observation period of 168 hours; η = number of patients. Student's t-test: * ρ < 0.05
a: Mean 2'-5'-oligoadenylate synthetase activity in serum
-o- 5 χ 106 IU, η = 13; - Δ - 3 χ ΙΟ6 IU, η = 13; -D- l χ ΙΟ6 IU, n = 10
b: Mean 2'-5'-oligoadenylate synthetase activity in leukocytes
-o- 5 χ 106 IU, n = 10; - Δ - 3 χ ΙΟ6 IU, n = 10; -D- l χ ΙΟ6 IU, n = 7
c: 2'-5'-oligoadenylate synthetase activity in serum after application of 3 χ ΙΟ6 IU interferon beta (3 randomly chosen
patients)
d: 2'-5'-oligoadenylate synthetase activity in lysates of leukocytes after application of 3 χ ΙΟ6 IU interferon-beta (same
patients as shown in fig. 5c)
e: Interferon beta [103 IU/1] in serum of these three patients.
tion of recombinant interferon beta and gamma. In
order to answer this question we determined the ac-
tivity of 2/-5/-oligoadenylate synthetase in leukocytes
(radioenzymatic assay) and in serum samples using a
new commercial radioimmunoassay. This latter assay
proved to be very practical and yielded well repro-
ducible results. Basal 2'-5'-oligoadenylate synthetase
catalytic concentrations of healthy donors were estab-
lished and found to be within a range similar to that
reported elsewhere (27). To obtain accurate results
with this assay, it is obviously important to separate
the serum immediately after the drawing of blood and
coagulation, since blood storage causes an increase in
the 2'-5'-oligoadenylate synthetase due to release of
the enzyme from blood cells (27).
The fundamental pattern of 2'-5'-oligoadenylate syn-
thetase activity in serum was found to be similar to
that in leukocytes. However, in contrast to reported
data (27), we could not find a direct correlation be-
tween 2/-5/-oligoadenylate synthetase in serum and
2/-5/-oligoadenylate synthetase in leukocytes from the
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 30,1992 / No. 9
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Fig. 6. 2/-5/-Oligoadenylate synthetase activity in serum and leukocytes after a single s.c. injection of 2 and 4 χ ΙΟ6 IU (100 and
200 μg, respectively) interferon gamma during an observation period of 168 hours; η = number of patients.
Student's t-test: * ρ < 0.05
a: Mean 2'-5'-oligoadenylate synthetase activity in serum
-O- 200 μ& η = 16 - Δ - 100 μ& η = 13
b: Mean 2'-5'-oligoadenylate synthetase activity in leukocytes
- Δ - 200 μ& η = 10 -Ο- 100 μ& η = 11
c: 2'-5'-Oligoadenylate synthetase activity in serum after application of 4 χ ΙΟ6 IU interferon gamma (3 randomly chosen
patients)
d: 2/-5/-Oligoadenylate synthetase activity in lysates of leukocytes after application of 4 χ ΙΟ6 IU interferon gamma (same
patients as shown in fig. 6c)
e: Interferon gamma [103 IU/1] in serum of these three patients.
same blood sample. This raises the question of where
the serum 2/-5/-oligoadenylate synthetase comes from.
Based on the data of our investigation and on theo-
retical considerations, it is improbable that 2'-5'-oli-
goadenylate synthetase released from mononuclear
blood cells is the main source of the activity in serum.
Since 2/-5/-oligoadenylate synthetase can be induced
in many cells, this enzyme may be released from
almost every cell in the body which had previously
come in contact with interferon. Main potential
sources are, e.g. cells at and near to the site of
interferon injection. In blood, granulocytes may play
an even more important role than mononuclear blood
cells, because their 2/-5/-oligoadenylate synthetase can
be easily induced (28), they are fragile, present in high
numbers, and have a short half life. However, what-
ever the source of 2/-5/-oligoadenylate synthetase, its
estimation in serum proved to be as informative as
its estimation in leukocytes. Moreover, the enzyme
immunoassay in serum is much easier to perform than
the radioenzymatic assay. Results of both assays
showed that after subcutaneous application of more
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 30,1992 / No. 9
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Fig. 7. Mean 2'-5'-oligoadenylate synthetase activity in leuko-
cytes during an observation period of 168 hours after
daily (7 days) s. c. injections of interferon gamma;
a) 100 μ& η = 8; b) 200 μ& η = 6;
η = number of patients.
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Fig. 8. Mean 2'-5'-oligoadenylate synthetase activity in leuko-
cytes during an observation period of 168 hours after
daily (7 days) s. c. injections of interferon beta;
a) 3 χ 106 IU, η = 8; b) 5 χ 106 IU, η = 5;
η = number of patients.
than 1 χ 106 IU interferon beta, 2/-5/-oligoadenylate
synthetase activity can be clearly detected; its deter-
mination proved to be much more sensitive than the
estimation of interferon. In contrast, interferon
gamma caused only a small elevation of 2'-5'-oli-
goadenylate synthetase and, therefore, its determina-
tion as a follow up marker during single dose therapy
is not recommended. 2/-5/-Oligoadenylate synthetase
catalytic concentrations were well elevated after ther-
apy with interferon beta, but not after therapy with
interferon gamma; as shown in table 1, similar results
were obtained for the in vitro stimulation of the
enzyme levels. Interestingly, during a daily application
therapy of interferon beta, the 2'-5'-oligoadenylate
synthetase activity dropped 2 — 3 days after the first
injection. This is obviously due to interferon recep-
tor down regulation phenomena (29). These data sug-
gest that daily application of interferon beta should
not be recommended for therapy. The schedule of
interferon application was therefore changed for the
therapy of further patients. In contrast, daily appli-
cation of interferon gamma showed a permanent in-
crease of 2/-5/-oligoadenylate synthetase activity dur-
ing the observation period of 7 days.
In conclusion, 2/-5/-oligoadenylate synthetase proved
to be a useful marker for optimizing subcutaneous
therapy with recombinant interferon beta and
gamma. The newly introduced radioimmunoassay
which permits a rapid and convenient determination
of this enzyme in serum is well suited for this purpose
and superior to other methods used so far.
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